一种新型的BAFF/APRIL双抑制剂用于治疗耐火性自身免疫性肝炎
Tianyu Mao1, Xiong Ma1, Xiao Xiao1
1Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai, China.
概括
作为BAFF/APRIL双重抑制剂的Telitacicept表明,它可以作为一种救援疗法来治疗自身免疫性肝炎 (AIH) 患者,这些患者对标准治疗不耐药. 这种新的方法在两个案例研究中证明了安全性和有效性,使免疫抑制减少.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 自身免疫性肝炎 (AIH) 是一种慢性肝病,其中有一部分患者表现出对常规疗法的耐药性.
- 治疗失败和AIH频繁复发需要探索替代治疗策略.
- 乙细胞激活因子 (BAFF) 和诱导增殖的甲配体 (APRIL) 是关键的细胞因子,与乙细胞存活和自身免疫病原发生有关.
研究的目的:
- 评估telitacicept的疗效和安全性,BAFF/APRIL双抑制剂,作为耐火性自身免疫性肝炎患者的救援疗法.
- 评估telelitacicept在降低疾病活性的潜力,并使标准免疫抑制剂的剂量减少.
主要方法:
- 两名自身免疫性肝炎患者的案例研究,他们未能对标准治疗做出反应.
- 用telitacicept治疗,这是一个BAFF/APRIL双抑制剂.
- 监测肝酶,免疫球蛋白G水平和药物剂量.
主要成果:
- 第一个患者对多种免疫抑制剂耐药且依赖于类固醇,经历了转氨酶和免疫球蛋白G的显著减少,允许类固醇逐渐减少.
- 第二名患者也被诊断为全身性红斑狼,实现了持续缓解,并减少了类固醇和mycophenolate mofetil的剂量.
- 在这两位患者的telitacicept治疗期间,没有观察到任何严重的不良事件.
结论:
- 泰利塔西显示出作为耐火性自身免疫性肝炎患者安全有效的救援疗法的潜力.
- 用telitacicept针对BAFF/APRIL可能为难以治疗的AIH病例提供一个有价值的治疗选择.
- 需要在更大的队列中进行进一步的研究,以证实这些有希望的发现.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
459
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
459
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
445
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
445
Autoimmune Disorders
1.4K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
1.4K
Inflammatory Bowel Disease IV: Pharmacological Management
445
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
445
Drugs for Treatment of Ulcerative Colitis in IBD
424
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
424


